一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括Bevacizumab；FOLFIRI；Pelareorep，当前状态为招募中。登记地点显示中国Homewood、Beverly Hills、Encino、Koreatown等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Bevacizumab；FOLFIRI；Pelareorep · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Central Alabama Research · Homewood
- Clinical Research Advisors (Beverly Hills) · Beverly Hills
- Clinical Research Advisors (Encino) · Encino
- Clinical Research Advisors (Korea Town) · Koreatown
- Clinical Research Advisors (Downtown LA) · Los Angeles
- Clinical Research Advisors (West Hollywood) · Los Angeles
- Clinical Research Advisors (West Covina) · West Covina
- Emory Winship Cancer Institute · Atlanta
- Beacon Cancer Center · Post Falls
- Community Health Network · Indianapolis
- Karmanos Cancer Institute · Detroit
- Washington University School of Medicine · St Louis
- Summit Health Cancer Center · Florham Park
- Rutgers Cancer Institute · New Brunswick
- Gabrail Cancer Center · Canton
公开的入选条件
- * Histologically confirmed cancer of the colon or rectum with documented metastasis
- * Measurable disease per RECIST v. 1.1
- * Not candidates for curative surgery or curative radiation
- * Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin
- * Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
- * Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
- * Tumor confirmed to harbor a known RAS mutation per a standard local testing method
- * ECOG performance status of 0 or 1
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07446322；登记信息更新于 2026-09-16。